Brind.
  1. A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.

Pfizer acquired Biohaven's migraine business, requiring FDA approval for the resulting drug launch.

1 report, 1 independent Updated Sep 4
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Pfizer acquired Biohaven's migraine business, requiring FDA approval for the resulting drug launch.

Who's involved

What this event is mainly about

How it developed

Newest first. Tap a step to see who reported it.
  1. FDA accepted Pfizer's New Drug Application (NDA) for vepdegestrant, supporting the company's growth trajectory.Sub-event
  2. Pfizer acquired Biohaven's migraine business, necessitating FDA approval for the drug launch.1 source

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • BioPharma DiveBiohaven’s rare disease drug is ‘ready to ship on Day 1’ following FDA approval This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily